Watch CBS News

Ann Arbor

adeona2.jpg

Adeona, Intrexon Collaborate For Synthetic DNA Therapy for Pulmonary Arterial Hypertension

The Ann Arbor pharmaceutical firm Adeona Pharmaceuticals Inc. and the Human Therapeutics Division of Intrexon Corp., Monday announced the formation of a global exclusive channel collaboration through which Adeona intends to develop and commercialize a DNA-based therapeutic using Intrexon's UltraVector platform and RheoSwitch Therapeutic System for the treatment of pulmonary arterial hypertension.

Show More
View CBS News In
CBS News App Open
Chrome Safari Continue